Conditional rates of problem behavior for weeks that followed medication decreases and no medication changes were compared for 12 individuals who exhibited severe problem behavior (e.g., self-injury, aggression). The results indicate that conditional rates of problem behavior were higher following medication decreases than following no changes in medication. During the subsequent week, rates of problem behavior typically decreased without reinstating the prior dosage of medication. Additional analyses suggest that the first medication decrease typically produced the highest increase in problem behavior. Decreases in medication also disrupted sleep patterns for several individuals. Possible operant conceptualizations of behavior changes produced by medication decreases are discussed.
American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author .
2.
Branch, M.N. (2006). How research in behavioral pharmacology informs behavioral science. Journal of the Experimental Analysis of Behavior, 85, 407-423.
3.
Green, V.A., Pituch, K.A., Itchen, J., Choi, A., O'Reilly, M., & Sigafoos, J. (2006). Internet survey of treatments used by parents of children with autism. Research in Developmental Disabilities , 27, 70-84.
4.
Holden, B., & Gitlesen, J.P. (2004). Psychotropic medication in adults with mental retardation: Prevalence, and prescription practices . Research in Developmental Disabilities, 25, 509-521.
5.
Kennedy, C.H., Caruso, M., & Thompson, T. (2001). Experimental analyses of gene-brain-behavior relations: Some notes on their application. Journal of Applied Behavior Analysis, 34, 539-549.
6.
McAdam, D.B., Zarcone, J.R., Hellings, J., Napolitano, D.A., & Schroeder, S.R. (2002). Effects of risperidone on aberrant behavior in persons with developmental disabilities: II. Social validity measures. American Journal on Mental Retardation , 107, 261-269.
7.
McKerchar, P.M., & Thompson, R.H. (2004). A descriptive analysis of potential reinforcement contingencies in the preschool classroom. Journal of Applied Behavior Analysis, 37, 431-444.
8.
Nagaraj, R., Singhi, P., & Malhi, P. (2006). Risperidone in children with autism: Randomized, placebo-controlled, double-blind study. Journal ofChild Neurology , 21, 450-455.
9.
O'Reilly, M.F. (1995). Functional analysis and treatment of escape-maintained aggression correlated with sleep deprivation. Journal of Applied Behavior Analysis, 28, 225-226.
10.
Pandina, G.J., Aman, M.G., & Findling, R.L. (2006). Risperidone in the management of disruptive behavior disorders. Journal of Child and Adolescent Psychopharmacology, 16, 379-392.
11.
Reyes, M., Buitelaar, J., Toren, P., Augustyns, I., & Eerdekens, M. (2006). A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. American Journal of Psychiatry , 163, 402-410.
12.
Ricketts, R.W., Goza, A.B., Ellis, C.R., Singh, Y.N., Singh, N.N., & Cooker, J.C. (1993). Fluoxetine treatment of severe self-injury in young adults with mental retardation. Journal of the American Academy of Child Psychiatry, 32, 865-869.
13.
Sevin, J.A., Bowers-Stephens, C., Hamilton, M.L., & Ford, A. (2001). Integrating behavioral and pharmacological interventions in treating clients with psychiatric disorders and mental retardation. Research in Developmental Disabilities, 22, 463-485.
14.
Sloman, K.N., Vollmer, T.R., Cotnoir, N.M., Borrero, C.S., Borrero, J.C., Samaha, A.L., et al. (2005). Descriptive analyses of caregiver reprimands . Journal of Applied Behavior Analysis, 38, 373-383.
15.
Spreat, S., Conroy, J.W., & Fullerton, A. (2004). Statewide longitudinal survey of psychotropic medication use for persons with mental retardation: 1994 to 2000. American Journal on Mental Retardation, 109, 322-331.
16.
Spreat, S., Conroy, J.W., & Jones, J.C. (1997). Use of medication in Oklahoma: A statewide survey . American Journal on Mental Retardation, 102, 80-85.
17.
Valdovinos, M.G., Caruso, M., Roberts, C., Kim, G., & Kennedy, C.H. (2005). Medical and behavioral symptoms as potential side effect in adults with developmental disabilities. American Journal on Mental Retardation, 111, 164-170.
18.
Valdovinos, M.G., & Kennedy, C.H. (2004). A behavior-analytic conceptualization of the side effects of psychotropic medication. TheBehavior Analyst, 27, 231-238.
19.
Vollmer, T.R., Borrero, J.C., Wright, C.S., Van Camp, C., & Lalli, J.S. (2001). Identifying possible contingencies during descriptive analyses of severe behavior disorders. Journal of Applied Behavior Analysis, 34, 269-287.
20.
Yoo, J.H., Williams, D.C., Napolitano, D.A., Peyton, P.T., Baer, D.M., & Schroeder, S.R. (2003). Rate-decreasing effects of the atypical neuroleptic risperidone attenuated by conditions of reinforcement in a woman with mental retardation. Journal of Applied Behavior Analysis, 36, 245-248.
21.
Zarcone, J.R., Hellings, J.A., Crandall, K., Reese, R.M., Marquis, J., Fleming, K., et al. (2001). Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. American Journal on Mental Retardation , 106, 525-538.
22.
Zarcone, J.R., Lindauer, S.E., Morse, P.S., Crosland, K.A., Valdovinos, M.G., & McKerchar, T.L. (2004). Effects of risperidone on destructive behavior of persons with developmental disabilities: III. Functional analysis. American Journal on Mental Retardation, 109, 310-321.
23.
Zubieta, J.K., & Alessi, N.E. (1992). Acute and chronic administration of trazodone in the treatment of disruptive behavior disorders in children. Journal of Clinical Psychopharmacology, 12, 346-351.
